Key result
Beta-blockers linked to ~18% lower COVID-19 risk in hypertensive adults.
Why the study?
The clinical usefulness of various cardiovascular drugs in hypertensive COVID-19 patients is debated, with uncertain effects on COVID-19 incidence and mortality.
Cohort (n=101,657)
Odds Ratio: 0.82 (95% CI 0.69–0.98)
p-value: p=0.029
PURPOSE: We aimed to investigate whether the use of cardiovascular drugs in coronavirus disease 2019 (COVID-19) patients with hypertension as a comorbidity has a significant effect on the incidence and associated mortality rate of COVID-19. MATERIALS AND METHODS: Data covering the period between January 1, 2020 and June 4, 2020 were extracted from The National Health Insurance Service-COVID-19 (NHIS-COVID-19) database in South Korea and analyzed as a population-based cohort study. RESULTS: =0.012). The use of other cardiovascular drugs was not associated with the incidence of COVID-19 or hospital mortality rate among COVID-19 patients. Similar results were observed in all 328374 adults in the NHIS-COVID-19 database, irrespective of the presence of hypertension. CONCLUSION: In South Korea, beta-blockers exhibited potential benefits in lowering the incidence of COVID-19 among hypertensive patients. Furthermore, CCBs may lower the hospital mortality rate among hypertensive COVID-19 patients. These findings were also applied to the general adult population, regardless of hypertension.
No takes yet. Share an insight, caveat, or question.
Oh et al. (2021) conducted a cohort in Hypertension (n=101,657). Beta-blockers vs. Non-users of beta-blockers was evaluated on Development of COVID-19 (incidence) (OR 0.82, 95% CI 0.69-0.98, p=0.029). Beta-blocker use was associated with an 18% lower incidence of COVID-19 compared to non-users among hypertensive adults (OR 0.82).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: